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Each year more than 600,000 arterial bypass grafts are
performed in the United States with autologous vein
grafts. The development of intimal hyperplasia remains the
major limitation to the long-term outcome of vein
grafts.1-3 Endothelial injury is a recognized precursor to
the formation of intimal hyperplasia.4-6 Many factors are
believed to contribute to the formation of intimal hyper-
plasia in vein grafts, including hemodynamic forces, neu-
trophil-endothelial interaction, platelet activation, growth
and coagulation factors, and cytokines.6,7
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Tissue factor (TF), a transmembrane glycoprotein,
functions as a cell surface receptor for the serine pro-
tease–activated factor VII (VIIa).8 The assembly of the TF
and VIIa results in the activation of factors IX and X, lead-
ing to the generation of thrombin and formation of fibrin
in the extrinsic coagulation pathway.8,9 Thrombin, fi-
brinogen, and activated factor X (Xa) have been shown to
stimulate the migration and proliferation of vascular
smooth muscle cells.6,10-12 In addition, thrombin and fi-
brinogen are potent platelet activators and promoters of
leukocyte chemotaxis.6,7,12 In balloon-injured arteries,
there is a rapid and short-lasting (less than 12-24 hours)
increase in TF expression.13,14 TF-mediated thrombin
generation has been shown to play an important role in
the pathogenesis of intimal hyperplasia in several arterial
injury models.15-18
The response of veins to arterial bypass graft surgery is
different from the well-described responses of arteries to
balloon injury.7,13,19-21 In a well-established model of vein
grafts implanted into the arterial circulation, we have
demonstrated that an inflammatory response, consisting
predominantly of polymorphonuclear leukocytes, begins
within 6 hours and persists for 5 to 7 days after bypass
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Background: Tissue factor (TF)–initiated thrombin generation has been implicated in the development of intimal hyper-
plasia after arterial injury. An increase in intimal TF expression has been shown to precede the development of intimal
hyperplasia in vein grafts. This study examines the effects of local treatment with recombinant human tissue factor
pathway inhibitor (rTFPI) in experimental vein grafts.
Methods: Thirty-six male New Zealand white rabbits underwent bypass grafting of the carotid artery by use of the
reversed ipsilateral jugular vein and were divided into four groups. Twenty animals had ex vivo incubation with rTFPI
treatment (50 µg · mL–1; n = 10) or placebo vehicle (control; n = 10). Sixteen animals received both ex vivo incuba-
tion and in vivo gel treatment with rTFPI (50 µg · mL–1; n = 8) or without rTFPI (gel-control; n = 8). After opera-
tion, vein grafts were harvested at 3 days for immunohistochemical and Western analyses and at 28 days for
histomorphologic study.
Results: Western analysis demonstrated a 6.2-fold reduction in the expression of TF protein with rTFPI treatment in
comparison to without rTFPI treatment. CD-18 leukocyte staining was diminished, whereas Tie-2 endothelial staining
was increased in all rTFPI-treated vein grafts, compared with control and gel-control vein grafts. Intimal thickness was
reduced by 21% with ex vivo rTFPI treatment compared with placebo (69 ± 4 versus 87 ± 5 µm; P < .05) and by 30%
with the addition of rTFPI in vivo compared with gel-control (60 ± 4 versus 86 ± 5 µm; P < .01).
Conclusion: Local administration of rTFPI exerts early beneficial effects and limits the development of intimal hyper-
plasia in vein grafts. Therefore blocking TF-mediated pathway may offer new therapeutic options to reduce vein graft
failure. (J Vasc Surg 2001;33:400-7.)
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grafting; the development of intimal hyperplasia in vein
grafts starts microscopically at 5 to 7 days, accelerates, and
reaches a plateau by 28 days.5,7 We recently reported spa-
tial and temporal changes in TF protein expression in veins
after bypass grafting in the same model.22 The major find-
ings in this study were an increase in intimal TF protein for
at least 3 days and colocalization of TF protein with CD-
18 leukocyte positive immunostaining in the intima.22
The alterations in TF protein expression in vein grafts dif-
fer from the changes seen in balloon-injured arteries. The
changes in TF protein precede the development of intimal
hyperplasia in both vein grafts and balloon-injured arter-
Fig 1. Immunohistochemistry of representative sections from ungrafted contralateral jugular vein (A and B), 3-day gel-control vein graft
(C and D), and 3-day rTFPI-in-gel vein graft (E and F). Endothelial cell staining (red) was assessed by use of murine antibody raised
against human Tie-2, endothelial cell–specific tyrosine kinase receptor. Murine monoclonal anti-rabbit CD-18, which detects β2 chain
of leukocyte adherence complex in activated neutrophils and monocytes (red), was used to determine inflammatory infiltrate. In jugu-
lar veins, Tie-2 staining was uniform in endothelial cells (A) and CD-18–positive leukocytes were infrequently present (B). At 3 days
after operation, Tie-2 staining was virtually absent (C) and CD-18–positive leukocytes were markedly increased (D) in gel-control vein
grafts. Treatment with rTFPI-in-gel preserved endothelial Tie-2 staining (E) and decreased the presence of CD-18 positive leukocytes
(F) in vein grafts at 3 days. Note that Tie-2 staining in rTFPI-in-gel vein grafts was similar to that in ungrafted jugular veins (E versus
A, respectively). Vessel lumen is at top in all sections. Original magnification × 50 in all panels.
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ies, but the precise role of TF in the hyperplastic response
seen in vein grafts is still unknown.
Tissue factor pathway inhibitor (TFPI), a Kunitz-type
protease inhibitor produced predominantly by endothelial
cells, provides negative feedback on the TF-initiated coagula-
tion pathway in two steps: first, by binding to TF/VIIa com-
plex and second, by binding to Xa, forming a quaternary
inhibitory complex consisting of TF/VIIa/Xa/TFPI.23,24
Our hypothesis was that TF-initiated coagulation pathway
may be involved in the early inflammatory response and
endothelial alterations, both of which precede the develop-
ment of intimal hyperplasia in vein grafts. The aim of this
study was to assess whether TF-initiated coagulation path-
way plays a role in the hyperplastic development of intimal
hyperplasia in vein grafts. We therefore treated experimen-
tal vein grafts with rTFPI, a human recombinant protein,
and examined the short- and long-term effects of blocking
TF-initiated coagulation pathway.
METHODS
Experimental protocol. Thirty-six New Zealand
white rabbits underwent interposition bypass grafting of
the right carotid artery with the reversed ipsilateral jugu-
lar vein as previously described.5,22,25,26 The harvested
jugular veins were incubated in Ringer’s lactated buffer
containing rTFPI 50 µg · mL–1 (Monsanto/Searle Co, St
Louis, Mo, and Chiron Corp, Emoryville, Calif) for 15
minutes at 37° C before grafting to study the effects of ex
vivo treatment. It was hypothesized that prolonged local
delivery of rTFPI may provide greater effects. Combined
ex vivo and in vivo rTFPI treatment was administered,
with the addition of rTFPI (50 µg · mL–1) to 30% pluronic
gel 2 mL (BASF, Washington, NJ), which was then
applied in vivo, to coat the external surface of the vein
graft before wound closure (rTFPI-in-gel). We have previ-
ously used pluronic gel to effectively deliver pharmaco-
logic agents; the gel is in a liquid form at 4°C, semisolid at
37°C, and reabsorbed within 24 to 72 hours.25 Control
animals received only ex vivo placebo vehicle (control) or
in vivo gel treatment without rTFPI (gel-control). Vein
grafts and contralateral jugular veins were harvested on
the third day after operation for Western blot and
immunohistochemical analyses to study the short-term
effects of rTFPI. Vein grafts were harvested for histomor-
phometric assessment on the 28th day after operation to
examine the long-term effects of rTFPI.
On the day of harvest, animals were anesthetized and
subsequently killed with an intravenous overdose of barbi-
turates.5,22,25,26 All procedures performed on animals
were approved by the Duke University Institutional
Animal Care and Use Committee. Animal care and han-
dling complied with the Guide for the Care and Use of
Laboratory Animals issued by the Institute of Laboratory
Animal Resources Commission on Life Sciences, National
Research Council (National Academy Press, Washington,
DC, 1996).
Immunohistochemical analysis. The effects of rTFPI
treatment on the inflammatory infiltration and on the
endothelium of 3-day vein grafts were examined with
Fig 2. Representative Western blot analysis of total TF protein in
ungrafted jugular veins and 3-day vein grafts. TF protein was
detected as band just above 43-kDa molecular weight marker, by
use of AP-1, antibody that has been shown to block TF-mediated
thrombosis both in vitro and in vivo.28,29 Equal amounts (10 µg)
of protein were loaded in each lane. A, Compared with their
respective contralateral ungrafted jugular veins (lanes 1 and 3), total
TF proteins were similar in 3-day control vein grafts (lane 2) and
3-day gel-control vein grafts (lane 4). B, In contrast, there is
marked reduction in total TF protein in 3-day rTFPI-in-gel vein
grafts (lanes 2 and 4), compared with corresponding contralateral
ungrafted jugular veins (lanes 1 and 3).
Fig 3. Densitometric analysis of total TF protein expression in 3-
day rTFPI-in-gel and gel-control vein grafts. For each vein graft,
total TF protein was expressed as densitometric ratio (densito-
metric ratio = integrated density of TF band in vein graft/inte-
grated density of TF band in corresponding contralateral jugular
vein). Combined ex vivo and in vivo treatment with rTFPI
reduced total TF protein by 6.2-fold as compared with gel-con-
trol (densitometric ratio: 0.12 ± 0.02 versus 0.74 ± 0.07, respec-
tively; P < .05). Values are means ± SEM (n = 3 animals per
group). Statistical differences between two groups were com-
pared by use of Mann-Whitney rank sum test.
A B
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immunohistochemistry. Distal and proximal segments (5-
10 mm) of 3-day vein grafts and contralateral jugular veins
(n = 4 for rTFPI and control groups; n = 3 for rTFPI-in-
gel and gel-control groups) were washed gently in ice-cold
phosphate-buffered saline solution (PBS). The steps used
in specimen processing and immunohistochemical detec-
tion of leukocytic infiltration (CD-18) and endothelial cells
(Tie-2) were previously described.22,27 Briefly, specimens
were immediately placed in 30% sucrose in PBS at 4°C for
2 hours, embedded in OCT compound (Miles Inc, Elkhart,
Ind), and frozen in liquid nitrogen. Representative sections
were cut (5-6 µm), prepared on silane-coated microscope
slides, and stored at –80°C. Slides were thawed at room
temperature (5-10 minutes) and fixed in ice-cold acetone
for 2 minutes. Blocking solution was applied to the sec-
tions for 30 minutes. This and all the following steps were
performed at room temperature. A murine monoclonal
antirabbit CD-18 (1:100 dilution; Serotec, Oxford,
United Kingdom), which detects the β2 chain of the leuko-
cyte adherence complex in activated neutrophils and
monocytes, was used to determine the extent of inflamma-
tory infiltration.22 The structural integrity of the endothe-
lium was assessed by applying a murine monoclonal
antibody (MoAb33, 1:100 dilution; provided generously
by Dr K. G. Peters, Duke University) raised against the
extracellular domain of human Tie-2 (also known as TEK),
a receptor tyrosine kinase, expressed exclusively in the vas-
cular endothelium.26,27 After 1 hour of incubation with the
respective primary antibody, a sequence of incubation with
biotinylated alkaline phosphatase conjugated antimouse
immunoglobulin G (IgG) and ABC reagent, according to
the manufacturer’s specifications (Vectastain ABC kit;
Vector Laboratories, Burlingame, Calif), was carried out.
Levamisole was added to block endogenous alkaline phos-
phatase activity. Immune complexes were detected by use
of the chromogenic alkaline phosphatase substrate vector
red. Tissue sections were then counterstained with hema-
toxylin, dehydrated, and mounted. At least three cross sec-
tions per vein grafts and jugular veins in each experimental
group were examined under light microscopy by an
observer blinded to the experimental group and assigned a
Fig 4. Composite photomicrograph of representative cross-sections from wall of 28-day rTFPI (A), control (B), rTFPI-in-gel (C), and
gel-control (D) vein grafts. Arrowheads delineate demarcation between intima and media. Vessel lumen is at top. IH, Intimal hyperpla-
sia; M, media. Original magnification × 250.
Fig 5. Cross-sectional thickness of intima and media of 28-day
rTFPI, control, rTFPI-in-gel, and gel-control vein grafts. Ex vivo
incubation treatment with rTFPI reduced intimal thickness by
21% in 28-day vein grafts, compared with control incubation (69
± 4 versus 87 ± 5 µm, respectively; P < .05). Combined ex vivo
and in vivo rTFPI treatment decreased intimal thickness by 30%
(60 ± 4 vs 86 ± 5 µm, respectively; P < .01), compared with gel-
controls. Medial thickness of 28-day rTFPI vein grafts was also
reduced by 20%, compared with controls (73 ± 3 versus 91 ± 5
µm, respectively; P > .05), and by 15% in rTFPI-in-gel vein grafts
compared with gel-controls (73 ± 4 versus 86 ± 4µm, respectively;
P > .05), although these findings were not statistically significant.
Table I. Immunohistochemical analysis
rTFPI- Gel-
Veins rTFPI Control in-gel control
Tie-2 +++ ++ + ++ +
CD-18 + ++ +++ ++ +++
Qualitative scoring of Tie-2 and CD-18 staining patterns in the ungrafted
jugular veins and 3-day vein grafts treated with ex vivo rTFPI, control, ex
vivo and in vivo rTFPI and gel-control. A score of + was given for weak
staining, ++ for intermediate staining, and +++ for intense staining, by an
observer blinded to the experimental groups.
A B DC
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qualitative score for the staining pattern (weak, intermedi-
ate, or intense).
Western blot analysis. The effects of rTFPI treatment
on TF protein expression in 3-day vein grafts were assessed
with Western blot analysis. Midsegments (1-2 cm) of the
rTFPI-in-gel and gel-control vein grafts and of the con-
tralateral jugular veins (n = 3; Table I) were washed in ice-
cold PBS, blotted dry, weighed, and immediately
snap-frozen in liquid nitrogen. Protein extraction steps
were as described previously.22 Briefly, tissues were ground
into a fine powder in a mortar and pestle (in liquid nitro-
gen) then immediately sonicated in ice-cold Tris-saline
buffer (1:4 weight/volume; 0.05 mol · L–1 Tris · HCl,
150 mmol · L–1 NaCl and pH 7.4). Insoluble debris was
pelleted in a microcentrifuge at 14,000 g for 5 minutes at
4°C. The protein concentration in the supernatant (from
total vessel extracts) was determined by use of the
Bradford assay (Biorad Laboratories, Richmond, Calif).
Equal amounts of proteins from vessel extracts (10 µg)
were separated by sodiumolodecyl sulfate–polyacrylamide
(12%) gel electrophoresis and transferred to a nitrocellu-
lose membrane. Nonspecific binding to the membrane
was blocked with 5% nonfat dry milk overnight incubation
at 4°C. The membrane was then probed with a previously
characterized monoclonal murine antirabbit TF antibody
(AP-1; 2 mg · mL–1)28,29 for 1 hour at room temperature.
Antibody binding was detected by incubating the mem-
brane with a horseradish peroxidase–conjugated goat anti-
mouse IgG (1:5000 dilution; Promega, Madison, Wis) at
room temperature for 30 minutes. Protein bands were
then visualized by use of an enhanced chemiluminescence
kit (Amersham, Arlington Heights, Ill) and autoradiogra-
phy. The autoradiographs were scanned and digitized, and
the integrated density of visualized bands was measured
(N.I.H. Image 2.1, National Institutes of Health,
Washington, DC). TF protein expression in each vein graft
was reported as a ratio of the integrated density of each
vein graft to the integrated density of the corresponding
contralateral jugular vein, which was used as the internal
control for the individual animal. The TF ratio of the vein
grafts were then compared between experimental groups.
Morphometric analysis. The long-term remodeling
effects of rTFPI treatment were assessed by histomorpho-
metric analysis of 28-day vein grafts. Twenty-eight–day vein
grafts were perfusion fixed in situ at 80 mm Hg with 2%
glutaraldehyde as previously described.5,25 Briefly, cross sec-
tions (3 per graft) from the midportion of vein grafts were
processed after standard histologic procedures, and speci-
mens were stained with a modified Masson’s trichrome and
Verhoeff ’s elastin stain.25 The morphologic condition of
vein grafts was examined under light microscopy. Dimen-
sional analysis was performed with computerized video-
morphometry (Innovision 150; American Innovision, Inc,
San Diego, Calif). The intimal, medial, and luminal areas
and perimeter of each cross section were measured. The
demarcation between the intima and media was defined as
that interface between the “criss-cross” orientation of the
smooth muscle cells in the former and the circular orienta-
tion of the smooth muscle cells in the latter. The outer limit
of the media was delineated by the interface between the
smooth muscle cells of the media and the connective tissue
of the adventitia. The thickness of the intima and media was
mathematically derived as were the intimal ratio [intimal
area/(intimal + medial areas)] and luminal index [luminal
diameter/(cross-sectional wall thickness)]. The luminal
index is a measure of the changes in luminal diameter in
relation to changes in wall thickness.
Data and statistical analysis. Values presented are
the mean ± SEM. The two-tailed Mann-Whitney rank sum
test was used for all statistical comparisons. A P value less
than .05 was regarded as significant. Tie-2 and CD-18
immunostaining of 3-day vein grafts were qualitatively
compared between experimental groups.
RESULTS
General effects of rTFPI. All animals survived, and
all vein grafts were patent at harvest. There were no ill
effects resulting from the surgery, control, or rTFPI treat-
ment. In particular, no excessive bleeding was noted with
rTFPI treatment.
Short-term effects of rTFPI on 3-day vein grafts.
Three-day vein grafts were examined for the presence of
Table II. Morphometric analysis of ex vivo rTFPI treatment
rTFPI Control 
(n = 6) (n = 6) P value
Luminal area (mm2) 26.7 ± 1.9 29.8 ± 2.8 .40
Intimal area (mm2) 1.24 ± 0.09 1.75 ± 0.18 < .05
Medial area (mm2) 1.30 ± 0.08 1.87 ± 0.16 < .05
Intimal ratio 0.47 ± 0.01 0.49 ± 0.01 .91
Luminal index 38.9 ± 2.1 33.4 ± 1.5 < .05
Wall dimensions of 28-day vein grafts treated with local ex vivo rTFPI incu-
bation or placebo (control). Values are the mean ± SEM. Statistical differ-
ences between the two groups were compared by use of the Mann-Whitney
rank sum test.
Intimal ratio, Intimal area/(intimal + medial areas); luminal index, lumi-
nal diameter/(intimal + medial thickness).
Table III. Morphometric analysis of ex vivo and in vivo
rTFPI treatment
rTFPI-in-gel Gel-control 
(n = 5) (n = 5) P value
Luminal area (mm2) 21.3 ± 1.3 24.0 ± 2.4 .61
Intimal area (mm2) 0.94 ± 0.05 1.55 ± 0.16 < .01
Medial area (mm2) 1.20 ± 0.06 1.76 ± 0.16 < .05
Intimal ratio 0.44 ± 0.02 0.49 ± 0.01 < .05
Luminal index 38.7 ± 2.2 32.4 ± 2.0 < .05
Wall dimensions of 28-day vein grafts treated with both ex vivo incubation
and in vivo gel containing rTFPI (rTFPI-in-gel) or without rTFPI (gel-
control). Values are the mean ± SEM. Statistical differences between the
two groups were compared with the Mann-Whitney rank sum test.
Intimal ratio, Intimal area/(intimal + medial areas); luminal index, lumi-
nal diameter/(intimal + medial thickness). 
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Tie-2 staining in endothelial cells and CD-18 positive
staining leukocytes to determine whether rTFPI treatment
would have short-term beneficial effects. In the contralat-
eral jugular veins (ungrafted veins), Tie-2 staining was uni-
formly present in the luminal endothelial cells (Fig 1, A),
whereas CD-18–positive leukocytes were sparsely present
in the adventitia (Fig 1, B). Endothelial Tie-2 staining was
decreased in both gel-control (Fig 1, C) and control vein
grafts (not shown) when compared with ungrafted veins
(Fig 1, A). On the other hand, CD-18–positive leukocytes
were increased in both gel-control (Fig 1, D) and control
vein grafts (not shown) when compared with ungrafted
veins (Fig 1, B). Gel application alone did not seem to
alter Tie-2 staining in endothelial cells or the staining pat-
tern of CD-18 positive leukocytes (Table I). Local rTFPI
treatment, ex vivo or combined ex vivo and in vivo, pro-
duced similar Tie-2 and CD-18 staining patterns (Table
I). Endothelial Tie-2 staining was increased in rTFPI-in-
gel vein grafts (Fig 1, E) when compared with gel-control
vein grafts (Fig 1, C). Leukocytic CD-18 staining, in con-
trast, was reduced in rTFPI-in-gel–treated vein grafts (Fig
1, F) compared with gel-control vein grafts (Fig 1, D).
The pattern of Tie-2 endothelial staining and CD-18–pos-
itive leukocyte staining in rTFPI-treated vein grafts was
intermediate, between the staining pattern in ungrafted
jugular veins at one end and the untreated controls at the
other end (Table I).
TF protein expression was examined in 3-day vein
grafts to verify the early effect of rTFPI treatment on TF-
mediated pathway. Prior work from our laboratory has
shown that TF protein is increased in the intima of vein
grafts 3 days after bypass graft by immunohistochem-
istry.22 The same study also demonstrated that total
whole-wall (intima, media, and adventitia) TF protein in
3-day vein grafts is unchanged, as compared with the con-
trol contralateral (ungrafted) veins, by Western blot analy-
sis.22 Application of the pluronic gel in vivo without rTFPI
did not alter TF protein expression (Fig 2, A). Local treat-
ment with rTFPI-in-gel, however, reduced total TF pro-
tein as compared with control contralateral (ungrafted)
veins (Fig 2, B). Furthermore, with the contralateral jugu-
lar vein used as an internal control, the total TF protein
ratio in rTFPI-in-gel–treated vein grafts was reduced by
6.2-fold (P < .05) compared with the total TF protein
ratio in gel-control vein grafts (Fig 3). TF protein expres-
sion in 3-day vein grafts treated with ex vivo rTFPI only
was not significantly altered, when compared with 3-day
controls (data not shown).
Long-term effects of rTFPI on 28-day vein grafts.
Ex vivo incubation treatment with rTFPI reduced the
cross-sectional thickness of the intima in 28-day vein grafts
by 21%, compared with control incubation (69 ± 4 versus
87 ± 5 µm, respectively; P < .05, Figs 4 and 5). Combined
ex vivo and in vivo rTFPI treatment decreased intimal
thickness by 30% (60 ± 4 versus 86 ± 5 µm, respectively;
P < .01, Figs 4 and 5). The intimal areas of 28-day rTFPI
and rTFPI-in-gel vein grafts were also reduced by 29% and
39%, compared with Control and gel-control vein grafts,
respectively (Tables II and III). The cross-sectional medial
thickness of 28-day rTFPI vein grafts was also reduced by
20%, compared with controls (73 ± 3 versus 91 ± 5 µm,
respectively; P > .05; Figs 4 and 5), and by 15% in rTFPI-
in-gel vein grafts compared with gel-controls (73 ± 4 ver-
sus 86 ± 4 µm, respectively; P > .05; Figs 4 and 5),
although these findings were not statistically significant.
Similar reductions in the medial areas were observed in
28-day rTFPI (by 30%) and rTFPI-in-gel (by 32%) vein
grafts, as compared with their respective controls (Tables
II and III). Because of the greater decrease in the intimal
area than in the medial area, the intimal ratio was
decreased by only 10% in rTFPI-in-gel vein grafts, com-
pared with gel-control vein grafts (Table III). There were
no significant differences in luminal areas between rTFPI-
treated vein grafts and the respective controls (Tables II
and III). However, the luminal index was increased by
16% in 28-day rTFPI vein grafts as compared with con-
trols and by 19% in 28-day rTFPI-in-gel vein grafts as
compared with gel-controls (Tables II and III).
DISCUSSION
The long-term success of arterial bypass graft surgery
remains limited by the development of intimal hyperpla-
sia, which causes vein graft failure.2,3,6,7 The formation of
intimal hyperplasia is characterized by the migration and
proliferation of smooth muscle cells and is the precursor
to accelerated arteriosclerosis in human and experimental
vein grafts.3,4,6,7 Although a number of factors are con-
sidered to be involved in the hyperplastic response of vein
grafts, events that trigger this response remain ill
defined.6,7 Our study is the first report to show that a
pharmacologic agent, which blocks the extrinsic coagula-
tion pathway, can modulate the response of veins to
bypass. In the short-term, treatment with rTFPI reduced
the inflammatory infiltrate, prevented the loss of
endothelial staining, and attenuated TF protein expres-
sion. In the long-term, treatment with rTFPI decreased
the hyperplastic response in vein grafts without altering
luminal diameter.
The mechanisms by which rTFPI reduces intimal
hyperplasia are likely complex and may either involve the
inhibition of TF-initiated coagulation pathway or be medi-
ated directly by the rTFPI protein itself. We recently
reported that local delivery of a TF antibody (AP-1)
reduces early CD-18–positive leukocytic infiltration but
fails to limit both TF protein expression and intimal hyper-
plasia in the rabbit vein grafts.30 In this study we show that
combined ex vivo and in vivo rTFPI treatment significantly
attenuated TF protein expression, in addition to reducing
CD-18 positive leukocytic infiltration and preserving
endothelial Tie-2 staining. Because leukocyte infiltration
can contribute to endothelial injury by producing oxygen-
free radicals and promoting the release of cytokines and
proteases, the overall early effect of rTFPI treatment would
be to lessen the endothelial injury.5,6,21,31 Taken together,
these results further strengthen the role of TF-mediated
pathway in the development of intimal hyperplasia. A
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reduced TF expression could conceivably lead to less
thrombin generation and consequently decrease thrombin-
mediated effects. It is known that TF-mediated thrombin
generation may exert damaging effects on vein grafts by
promoting endothelial activation, stimulating platelet
aggregation, and potentiating the release of cytokines and
proteases.10,12,32-35 rTFPI may eliminate the mitogenic
effects of thrombin on vascular smooth muscle cells by
blocking TF-mediated thrombin generation.11
Interestingly, although ex vivo rTFPI treatment alone
failed to reduce TF protein expression significantly, it did
promote preservation of endothelial Tie-2 staining, reduce
CD-18–positive leukocytic infiltration, and decrease the
hyperplastic response in treated vein grafts. These findings
suggest that rTFPI may also exert effects that are, in part,
thrombin independent. For instance, rTFPI can abrogate
the migration of vascular smooth muscle cells induced by
TF, which has been shown to have in vitro chemoattrac-
tant effects comparable to platelet-derived growth factor
and basic fibroblast growth factor.36 Furthermore, direct
in vitro dose-dependent inhibition of human neonatal aor-
tic smooth muscle cell proliferation by rTFPI has been
shown by Kamikubo et al.37 On the other hand, Hamuro
et al38 recently reported rTFPI-induced endothelial cell
apoptosis in culture, which would seemingly contradict
our present findings. Greeno et al,32 however, demon-
strated an association between increased TF activity on cell
surface and apoptosis of endothelial cells. Although it is
not clear whether the increased TF activity is the cause or
effect of endothelial cell apoptosis, we postulate that
reduced TF activity may be linked to the survival of
endothelial cells. All in all, these findings suggest that
rTFPI effects are complex and extend beyond its
inhibitory effects on TF/VIIa complex and Xa.
The role of TF-initiated coagulation cascade is well
established in acute thrombosis after either arterial injury
or vascular anastomosis.16,18,24,39-41 In a pig model of vein
grafts, Rapp et al41 reported that local administration of
rTFPI significantly enhanced graft patency at 1 and 7 days.
In their study, the concentration of rTFPI (90 µg · mL–1)
was in similar range to the dose used in our study, but the
delivery method was different (direct flush into the arteri-
otomy site), and intimal hyperplasia was not measured.
Dumanian et al40 showed that in vitro incubation of
human placental arteries with rTFPI reduced platelet
deposition at anastomotic sites by 42%. Rubin et al42
demonstrated that preincubation with rTFPI reduces fi-
brinogen deposition in polyester grafts by 36%. In this
study we show a marked reduction in TF protein in
rTFPI-treated vein. Altogether these findings support a
potential role for rTFPI in blocking TF-mediated events
to favorably alter the remodeling response in vein grafts.
Although we have shown that rTFPI treatment may
produce advantageous remodeling responses in vein grafts
at 3 and 28 days after operation, interpretation of these
results must be cautioned. The short-term effects of rTPFI
examined by immunohistochemistry (Tie-2 and CD-18
staining) were analyzed qualitatively, and interpretation of
these results is limited as such. Additionally, we have
demonstrated an association between the short- and long-
term effects of rTFPI but have not proved a causal rela-
tionship. The precise mechanisms by which rTFPI
treatment modulates the hyperplastic response in vein
grafts remain to be determined in future studies, such as
measurements of factor VII and X and thrombin in the
presence and absence of rTFPI.
In conclusion, local administration of rTFPI produces
early beneficial effects on the endothelium and significantly
limits the hyperplastic response in vein grafts. Moreover,
the results of our study suggest that blocking the initiation
of TF-mediated pathway with rTFPI may provide new
therapeutic options to reduce vein graft failure.
Technical assistance of Ms L. Barber (Duke
University) is greatly appreciated. Tie-2 antibody was
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